Physician profile
Edward E Okimoto
NPI 1104939289
$13,967.14
in general payments reported to CMS, 2019-2025
30 companies · $2,937 in 2025
The $2,937 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $1,237 · 2021: $1,817 · 2022: $1,901 · 2023: $1,409 · 2024: $2,935 · 2025: $2,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,270 · Education: $10.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,270.34 |
| Education | $10.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,364.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,895.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,769.51 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $1,247.96 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $1,162.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,024.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.86 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $700.41 | 2023-2025 | |
| Pfizer INC. | $593.01 | 2019-2025 | |
| Esperion Therapeutics, INC. | $320.33 | 2021-2025 | Nexletol |
| Corcept Therapeutics | $308.71 | 2020-2024 | Korlym |
| Gilead Sciences, INC. | $239.97 | 2019-2025 | |
| Amarin Pharma, INC. | $221.25 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $221.11 | 2025 | Ponvory, Fanapt |
| Kowa Pharmaceuticals America, INC. | $205.66 | 2019-2023 | Livalo, Seglentis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $143.84 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $131.39 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $100.99 | 2019-2022 | |
| Dexcom, INC. | $97.37 | 2024-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $94.22 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $83.27 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $69.29 | 2019 | |
| Xeris Pharmaceuticals, INC. | $58.80 | 2023-2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $43.01 | 2025 | Inspire |
| Lundbeck LLC | $33.88 | 2024 | Rexulti |
| Radius Health, INC. | $26.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.95 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.03 | 2025 | Rexulti |
| Insulet Corporation | $20.80 | 2023 | Omnipod |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Okimoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.